Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL

Published:2019-01 Issue:1 Volume:45 Page:61-67
ISSN:1677-6119
Container-title:International braz j urol
language:
Short-container-title:Int. braz j urol.

Author:

Iwamoto Hiroaki¹,Izumi Kouji¹^ORCID,Kadono Yoshifumi¹,Mizokami Atsushi¹

Affiliation:

1. Kanazawa University, Japan

Publisher

FapUNIFESP (SciELO)

Subject

Urology

Link

http://www.scielo.br/pdf/ibju/v45n1/1677-6119-ibju-45-01-0061.pdf

Reference17 articles.

1. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy;Kadono Y;World J Urol.,2016

2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D’Amico AV;JAMA.,1998

3. The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels;Izumi K;Prostate.,2015

4. Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level;Izumi K;J Cancer Res Clin Oncol.,2014

5. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide;Sheth AR;Indian J Exp Biol.,1992

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?;Clinical Genitourinary Cancer;2023-12

2. Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy;Annals of Medicine;2023-11-08

3. Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial;Clinical Genitourinary Cancer;2023-10

4. Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study;MIDDLE EAST J CANCER;2023

5. LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer;HISTOL HISTOPATHOL;2023